Search Results

By Matthew Stenger  / Friday, June 14, 2013 9:59 AM

Younger Age Does Not Significantly Impact Recurrence or Benefit from Trastuzumab in Early-stage HER2-positive Breast Cancer

Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...